- Home
- GYRE vs NRK Comparison
GYRE vs NRK Comparison
Compare GYRE & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- NRK
- Stock Information
- Founded
- GYRE 2002
- NRK 2002
- Country
- GYRE United States
- NRK United States
- Employees
- GYRE N/A
- NRK N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- NRK Trusts Except Educational Religious and Charitable
- Sector
- GYRE Health Care
- NRK Finance
- Exchange
- GYRE Nasdaq
- NRK Nasdaq
- Market Cap
- GYRE 897.1M
- NRK 922.1M
- IPO Year
- GYRE N/A
- NRK N/A
- Fundamental
- Price
- GYRE $9.53
- NRK $10.06
- Analyst Decision
- GYRE
- NRK
- Analyst Count
- GYRE 0
- NRK 0
- Target Price
- GYRE N/A
- NRK N/A
- AVG Volume (30 Days)
- GYRE 105.9K
- NRK 187.3K
- Earning Date
- GYRE 05-09-2025
- NRK 01-01-0001
- Dividend Yield
- GYRE N/A
- NRK 4.10%
- EPS Growth
- GYRE N/A
- NRK N/A
- EPS
- GYRE 0.04
- NRK N/A
- Revenue
- GYRE $100,643,000.00
- NRK N/A
- Revenue This Year
- GYRE $22.01
- NRK N/A
- Revenue Next Year
- GYRE $88.14
- NRK N/A
- P/E Ratio
- GYRE $213.36
- NRK N/A
- Revenue Growth
- GYRE N/A
- NRK N/A
- 52 Week Low
- GYRE $6.11
- NRK $8.95
- 52 Week High
- GYRE $19.00
- NRK $11.09
- Technical
- Relative Strength Index (RSI)
- GYRE 55.67
- NRK 49.17
- Support Level
- GYRE $8.51
- NRK $10.02
- Resistance Level
- GYRE $9.98
- NRK $10.14
- Average True Range (ATR)
- GYRE 0.61
- NRK 0.08
- MACD
- GYRE 0.10
- NRK 0.03
- Stochastic Oscillator
- GYRE 73.84
- NRK 78.35
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.